An interventional study of Ranibizumab 0.5 mg in Macular Edema and Retinal Vein Occlusion, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-10.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one has the largest enrollment, is one of 5 that started in 2008, is one of 6 with no phase, and was the 34th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 608 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2008, is the only one with no phase, and was the 6th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort (reported here) enrolled subjects with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). Patients were enrolled within 14 days of completion of the previous study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
Drug: Ranibizumab 0.5 mg
Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
Also known as: Lucentis
Number of Participants With Ocular Adverse Events in the Study Eye
Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Time frame: Up to 24 months
Number of Participants With Non-ocular Adverse Events
Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.
Time frame: Up to 24 months
Change From Baseline in the Best Corrected Visual Acuity (BCVA)
Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.
Time frame: Baseline (Day 0 of extension study), Months 6, 12, 18, and 24
Change From Baseline in Central Foveal Thickness at Month 6 and Month 12
Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.
Time frame: Baseline (Day 0 of extension study), Months 6 and 12
Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)
NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24. Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).
Time frame: Baseline (Day 0 of extension study), Months 12 and 24
This is an open label multi-center extension study for participants who completed FVF4165g BRAVO (NCT00486018) or FVF4166g CRUISE (NCT0048583). Cohort 2 consists of enrolled participants with macular edema secondary to retinal vein occlusion (RVO).
| Milestone | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Started | 97 | 103 | 104 | 98 | 107 | 99 |
| Ranibizumab-treated subjects | 93 | 103 | 104 | 96 | 107 | 99 |
| Received study drug in extension study | 61 | 70 | 60 | 70 | 89 | 81 |
| Completed | 0 | 2 | 0 | 0 | 1 | 0 |
| Not completed | 97 | 101 | 104 | 98 | 106 | 99 |
| Withdrew: Adverse event | 2 | 2 | 2 | 1 | 2 | 0 |
| Withdrew: Death | 0 | 1 | 3 | 3 | 1 | 3 |
| Withdrew: Lost to follow-up | 5 | 5 | 1 | 1 | 3 | 3 |
| Withdrew: Physician decision | 1 | 1 | 2 | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 6 | 3 | 2 | 2 | 2 | 1 |
| Withdrew: Sponsor decision | 82 | 88 | 92 | 88 | 95 | 87 |
| Withdrew: Subject non-compliance | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Condition mandated other intervention | 1 | 1 | 2 | 0 | 0 | 2 |
Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
| participants | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Any ocular adverse event (AE) | 51 | 64 | 63 | 60 | 67 | 66 |
| Ocular AE leading to treatment discontinuation | 1 | 2 | 2 | 0 | 2 | 2 |
| Ocular serious adverse event | 2 | 4 | 6 | 5 | 10 | 3 |
| Intraocular inflammation | 0 | 0 | 0 | 2 | 3 | 1 |
| Cataract | 6 | 10 | 6 | 3 | 6 | 5 |
Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.
| participants | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Any non-ocular adverse event | 56 | 77 | 68 | 58 | 71 | 64 |
| Serious non-ocular adverse event | 10 | 15 | 18 | 16 | 21 | 20 |
| Non-ocular adverse event led to discontinuation | 1 | 0 | 1 | 0 | 1 | 0 |
| Death | 0 | 1 | 3 | 3 | 1 | 3 |
Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.
| letters | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Month 6 (n=88,96,98,90,101,91) | -0.1 ± 8.1 | -2.2 ± 10.5 | -1.3 ± 7.1 | -3.2 ± 10.4 | -4.1 ± 10.7 | -3.2 ± 9.7 |
| Month 12 (n=66,66,73,58,69,50) | 0.9 ± 6.9 | -2.3 ± 11.5 | -0.7 ± 7.3 | -4.2 ± 11.3 | -5.2 ± 13.8 | -4.1 ± 12.9 |
| Month 18 (n=23,26,32,31,26,22) | 0.5 ± 5.0 | -1.7 ± 6.3 | -6.1 ± 15.5 | -5.1 ± 14.6 | -6.1 ± 12.1 | -0.8 ± 10.9 |
| Month 24 (n=0,2,0,0,1,0) | NA ± NA | -4.5 ± 16.3 | NA ± NA | NA ± NA | -1.0 ± NA | NA ± NA |
Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.
| µm | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Month 6 (n=86,96,97,90,101,89) | 21.5 ± 131.6 | 36.8 ± 159.8 | 40.2 ± 117.4 | 87.4 ± 217.1 | 161.4 ± 289.1 | 94.6 ± 235.9 |
| Month 12 (n=62,65,72,56,69,51) | 3.7 ± 124.9 | 6.3 ± 163.7 | 35.3 ± 110.6 | 79.7 ± 199.4 | 88.3 ± 262.9 | 68.4 ± 252.7 |
NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24. Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).
| Scores on a scale | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) |
|---|---|---|---|---|---|---|
| Month 12 (n=64,65,72,58,67,50) | -0.3 ± 10.0 | -0.7 ± 9.7 | -0.7 ± 8.6 | 0.1 ± 10.5 | -1.0 ± 8.0 | -1.6 ± 7.7 |
| Month 24 (n=0,2,0,0,1,0) | NA ± NA | 6.2 ± 7.4 | NA ± NA | NA ± NA | -13.3 ± NA | NA ± NA |
Collected over Up to 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab (Sham) | — | 32/189 (16.9%) | 146/189 (77.2%) |
| Ranibizumab (0.3 mg) | — | 49/210 (23.3%) | 179/210 (85.2%) |
| Ranibizumab (0.5 mg) | — | 46/203 (22.7%) | 172/203 (84.7%) |
| Event | Ranibizumab (Sham) | Ranibizumab (0.3 mg) | Ranibizumab (0.5 mg) |
|---|---|---|---|
| VISUAL ACUITY REDUCEDEye disorders | 4/189 | 3/210 | 2/203 |
| MACULAR OEDEMAEye disorders | 1/189 | 2/210 | 4/203 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/189 | 4/210 | 2/203 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/189 | 4/210 | 0/203 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 1/189 | 1/210 | 3/203 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/189 | 2/210 | 1/203 |
| CORONARY ARTERY DISEASECardiac disorders | 2/189 | 0/210 | 2/203 |
| VITREOUS HAEMORRHAGEEye disorders | 2/189 | 1/210 | 0/203 |
| FALLInjury, poisoning and procedural complications | 2/189 | 1/210 | 1/203 |
| GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 1/189 | 0/210 | 2/203 |
| Event | Ranibizumab (Sham) | Ranibizumab (0.3 mg) | Ranibizumab (0.5 mg) |
|---|---|---|---|
| RETINAL HAEMORRHAGEEye disorders | 33/189 | 54/210 | 51/203 |
| CONJUNCTIVAL HAEMORRHAGEEye disorders | 29/189 | 37/210 | 31/203 |
| RETINAL VASCULAR DISORDEREye disorders | 19/189 | 29/210 | 21/203 |
| MACULOPATHYEye disorders | 21/189 | 19/210 | 19/203 |
| MACULAR OEDEMAEye disorders | 13/189 | 23/210 | 19/203 |
| HYPERTENSIONVascular disorders | 14/189 | 21/210 | 15/203 |
| NASOPHARYNGITISInfections and infestations | 14/189 | 13/210 | 8/203 |
| RETINAL EXUDATESEye disorders | 11/189 | 12/210 | 15/203 |
| VITREOUS DETACHMENTEye disorders | 9/189 | 9/210 | 15/203 |
| INTRAOCULAR PRESSURE INCREASEDInvestigations | 9/189 | 15/210 | 12/203 |
| Age, Customized(participants) | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) | Total |
|---|---|---|---|---|---|---|---|
| <45 years | 5 | 3 | 3 | 8 | 3 | 4 | 26 |
| 45 to <65 years | 43 | 39 | 38 | 37 | 26 | 32 | 215 |
| 65 to <85 years | 45 | 54 | 55 | 49 | 68 | 59 | 330 |
| ≥85 years | 4 | 7 | 8 | 4 | 10 | 4 | 37 |
| Sex: Female, Male(Participants) | Ranibizumab (Sham BRAVO) | Ranibizumab (0.3 mg BRAVO) | Ranibizumab (0.5 mg BRAVO) | Ranibizumab (Sham CRUISE) | Ranibizumab (0.3 mg CRUISE) | Ranibizumab (0.5 mg CRUISE) | Total |
|---|---|---|---|---|---|---|---|
| Female | 43 | 57 | 46 | 41 | 52 | 39 | 278 |
| Male | 54 | 46 | 58 | 57 | 55 | 60 | 330 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab